Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
15 "Computed tomography"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Preoperative Prediction Model for Early Recurrence of Intrahepatic Cholangiocarcinoma After Surgical Resection: Development and External Validation Study
Dong Hwan Kim, Sang Hyun Choi, Sehee Kim, Hyungjin Rhee, Eun-Suk Cho, Suk-Keu Yeom, Sumi Park, Seung Soo Lee, Mi-Suk Park
Received December 10, 2024  Accepted February 4, 2025  Published online February 5, 2025  
DOI: https://doi.org/10.4143/crt.2024.1187    [Accepted]
AbstractAbstract PDF
Purpose
We aimed to develop a preoperative risk scoring system to predict early recurrence (ER) of intrahepatic cholangiocarcinoma (ICCA) after resection, utilizing clinical and computed tomography (CT) features.
Materials and Methods
This multicenter study included 365 patients who underwent curative-intent surgical resection for ICCA at six institutions between 2009 and 2016. Of these, 264 patients from one institution constituted the development cohort, while 101 patients from the other institutions constituted the external validation cohort. Logistic regression models were constructed to predict ER based on preoperative variables and were subsequently translated into a risk-scoring system. The discrimination performance of the risk-scoring system was validated using external data and compared to the American Joint Committee on Cancer (AJCC) TNM staging system.
Results
Among the 365 patients (mean age, 62±10 years), 153 had ER. A preoperative risk scoring system that incorporated both clinical and CT features demonstrated superior discriminatory performance compared to the postoperative AJCC TNM staging system in both the development (area under the curve [AUC], 0.78 vs. 0.68; p=0.002) and validation cohorts (AUC, 0.69 vs. 0.66; p=0.641). The preoperative risk scoring system effectively stratified patients based on their risk for ER: the 1-year recurrence-free survival rates for the low, intermediate, and high-risk groups were 85.5%, 56.6%, and 15.6%, respectively (p<0.001) in the development cohort, and 87.5%, 58.5%, and 25.0%, respectively (p<0.001) in the validation cohort.
Conclusion
A preoperative risk scoring system that incorporates clinical and CT imaging features was valuable in identifying high-risk patients with ICCA for ER following resection.
  • 43 View
  • 6 Download
Close layer
Gastrointestinal cancer
Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy
Hyun Kyung Yang, Mi-Suk Park, Kyunghwa Han, Geonsik Eom, Yong Eun Chung, Jin-Young Choi, Seungmin Bang, Chang Moo Kang, Jinsil Seong, Myeong-Jin Kim
Cancer Res Treat. 2024;56(1):247-258.   Published online August 22, 2023
DOI: https://doi.org/10.4143/crt.2023.586
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Clinical prognostic criteria using preoperative factors were not developed for post–neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria.
Materials and Methods
Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system.
Results
One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, –0.012 to 0.142).
Conclusion
“Any degree of decrease in tumor size on CT” and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.
  • 2,865 View
  • 168 Download
Close layer
Hematologic Malignancy
Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma
Xiaoyan Feng, Xin Wen, Ling Li, Zhenchang Sun, Xin Li, Lei Zhang, Jingjing Wu, Xiaorui Fu, Xinhua Wang, Hui Yu, Xinran Ma, Xudong Zhang, Xinli Xie, Xingmin Han, Mingzhi Zhang
Cancer Res Treat. 2021;53(3):837-846.   Published online December 2, 2020
DOI: https://doi.org/10.4143/crt.2020.123
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There is no optimal prognostic model for T-cell lymphoblastic lymphoma (T-LBL). Here, we discussed the predictive value of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) measured on 18F-fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) in T-LBL.
Materials and Methods
Thirty-seven treatment naïve T-LBL patients with PET-CT scans were enrolled. TMTV was obtained using the 41% maximum standardized uptake value (SUVmax) threshold method, and TLG was measured as metabolic tumor volume multiplied by the mean SUV. Progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier curves and compared by the log-rank test.
Results
The optimal cutoff values for SUVmax, TMTV, and TLG were 12.7, 302 cm3, and 890, respectively. A high SUVmax, TMTV, and TLG indicated a shorten PFS and OS. On multivariable analysis, TMTV ≥ 302 cm3, and central nervous system (CNS) involvement predicted inferior PFS, while high SUVmax, TLG and CNS involvement were associated with worse OS. Subsequently, we generated a risk model comprising high SUVmax, TMTV or TLG and CNS involvement, which stratified the population into three risk groups, which had significantly different median PFS of not reached, 14 months, and 7 months for low-risk group, mediate-risk group, and high-risk group, respectively (p < 0.001). Median OS were not reached, 27 months, and 13 months, respectively (p < 0.001).
Conclusion
Baseline SUVmax, TMTV, and TLG measured on PET-CT are strong predictors of worse outcome in T-LBL. A risk model integrating these three parameters with CNS involvement identifies patients at high risk of disease progression.

Citations

Citations to this article as recorded by  
  • Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma
    Hazim S. Ababneh, Andrea K. Ng, Jeremy S. Abramson, Jacob D. Soumerai, Ronald W. Takvorian, Matthew J. Frigault, Chirayu G. Patel
    Hematological Oncology.2024;[Epub]     CrossRef
  • Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [ 18 F]FDG-PET/CT and bone marrow biopsy findings
    Xinyu Liang, Chunli Yang, Minggang Su, Liqun Zou
    Current Medical Research and Opinion.2024; 40(5): 803.     CrossRef
  • The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection
    Xia Lu, Ang Wei, Xu Yang, Jun Liu, Siqi Li, Ying Kan, Wei Wang, Tianyou Wang, Rui Zhang, Jigang Yang
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma
    Fei Liu, Bingxin Gu, Nan Li, Herong Pan, Wen Chen, Ying Qiao, Shaoli Song, Xiaosheng Liu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT
    Kwai Han Yoo
    Blood Research.2022; 57(S1): S75.     CrossRef
  • Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT
    Hongyan Li, Min Wang, Yajing Zhang, Fan Hu, Kun Wang, Chenyang Wang, Zairong Gao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T‐Cell Lymphoblastic Lymphoma
    Jin Zhao, Xiaojing Guo, Li Ma, Meijing Zheng, Tao Guan, Liping Su, Mohammad Farukh Hashmi
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • Clinical and prognostic role of 2-[18F]FDG PET/CT and sarcopenia in treatment-naïve patients with T-cell lymphoblastic lymphoma
    Xiaoyue Tan, Hui Yuan, Dongjiang Li, Xiaolin Sun, Chongyang Ding, Lei Jiang
    Annals of Hematology.2022; 101(12): 2699.     CrossRef
  • Prognostic value of baseline total metabolic tumour volume of 18F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma
    Huanyu Gong, Tiannv Li, Jianyong Li, Lijun Tang, Chongyang Ding
    EJNMMI Research.2021;[Epub]     CrossRef
  • 5,780 View
  • 182 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Gynecologic cancer
Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer
Young Shin Chung, Hyun-Soo Kim, Jung-Yun Lee, Won Jun Kang, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim
Cancer Res Treat. 2020;52(4):1211-1218.   Published online April 28, 2020
DOI: https://doi.org/10.4143/crt.2019.506
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to evaluate the ability of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) after one cycle of neoadjuvant chemotherapy (NAC) to predict chemotherapy response before interval debulking surgery (IDS) in advanced-stage ovarian cancer patients.
Materials and Methods
Forty consecutive patients underwent 18F-FDG-PET/CT at baseline and after one cycle of NAC. Metabolic responses were assessed by quantitative decrease in the maximum standardized uptake value (SUVmax) with PET/CT. Decreases in SUVmax were compared with cancer antigen 125 (CA-125) level before IDS, response rate by Response Evaluation Criteria in Solid Tumors criteria before IDS, residual tumor at IDS, and I chemotherapy response score (CRS) at IDS.
Results
A 40% cut-off for the decrease in SUVmax provided the best performance to predict CRS 3 (compete or near-complete pathologic response), with sensitivity, specificity, and accuracy of 81.8%, 72.4%, and 72.4%, respectively. According to this 40% cut-off, there were 17 (42.5%) metabolic responders (≥ 40%) and 23 (57.5%) metabolic non-responders (< 40%). Metabolic responders had higher rate of CRS 3 (52.9% vs. 8.7%, p=0.003), CA-125 normalization (< 35 U/mL) before IDS (76.5% vs. 39.1%, p=0.019), and no residual tumor at IDS (70.6% vs. 31.8%, p=0.025) compared with metabolic non-responders. There were significant associations with progression-free survival (p=0.021) between metabolic responders and non-responders, but not overall survival (p=0.335).
Conclusion
Early assessment with 18F-FDG-PET/CT after one cycle of NAC can be useful to predic response to chemotherapy before IDS in patients with advanced-stage ovarian cancer.

Citations

Citations to this article as recorded by  
  • The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients
    Daying Mou, Shengyan Xie, Pingyuan Li, Mohammad Farukh Hashmi
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • Radiomics Analysis of PET and CT Components of 18F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer
    Xihai Wang, Zaiming Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 8,348 View
  • 135 Download
  • 7 Web of Science
  • 2 Crossref
Close layer
SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer
Yoo-Kang Kwak, Hee Hyun Park, Kyu Hye Choi, Eun Young Park, Soo Yoon Sung, Sea-Won Lee, Ji Hyun Hong, Hyo Chun Lee, Ie Ryung Yoo, Yeon Sil Kim
Cancer Res Treat. 2020;52(1):85-97.   Published online May 17, 2019
DOI: https://doi.org/10.4143/crt.2019.007
AbstractAbstract PDFPubReaderePub
Purpose
Fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) is gaining evidence as a predictive factor in non-small cell lung cancer (NSCLC). Stereotactic ablative radiotherapy (SABR) is the standard treatment in early-stage NSCLC when a patient is unsuitable for surgery. We performed a study to assess the prognostic clinical significance of PET-CT after SABR in early-stage NSCLC.
Materials and Methods
Seventy-six patients with stage I NSCLC treated with SABR were investigated. Total radiation dose ranged from 36 to 63 Gy in three to eight fractions depending on tumor location and size. Respiratory motion control was implemented at simulation and during treatment. PET-CT prior to SABR was performed in 66 patients (86.8%).
Results
Median follow-up time was 32 months (range, 5 to 142 months). Local control rate at 1, 2, and 5 years were 95.9%, 92.8%, and 86.7%, respectively. Overall survival (OS) at 1, 2, and 5 years were 91.0%, 71.3%, and 52.1% respectively. Cause-specific survival at 1, 2, and 5 years were 98.6%, 93.1%, and 84.3% respectively. Tumor size and pre-SABR maximal standardized uptake value (SUVmax) demonstrated statistical significance in the Kaplan-Meier survival analyses with log-rank test. In multivariate analyses pre-SABR SUVmax remained statistically significant in correlation to OS (p=0.024; hazard ratio [HR], 3.2; 95% confidence interval [CI], 1.2 to 8.8) and with marginal significance in regards to regional progression-free survival (p=0.059; HR, 32.5; 95% CI, 2.6 to 402.5).
Conclusion
Pre-SABR SUVmax demonstrated a predictive power in statistical analyses. Tumors with SUVmax above 6 at diagnosis were associated with inferior outcomes.

Citations

Citations to this article as recorded by  
  • Enhanced NSCLC subtyping and staging through attention-augmented multi-task deep learning: A novel diagnostic tool
    Runhuang Yang, Weiming Li, Siqi Yu, Zhiyuan Wu, Haiping Zhang, Xiangtong Liu, Lixin Tao, Xia Li, Jian Huang, Xiuhua Guo
    International Journal of Medical Informatics.2025; 193: 105694.     CrossRef
  • Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer – Results from a Single Institution Study
    Benjamin George, Atallah Baydoun, Samar Bhat, Lauryn Bailey, Theodore Arsenault, Yilun Sun, Yuxia Zhang, Yiran Zheng, Prashant Vempati, Tarun Podder, Tithi Biswas
    Clinical Lung Cancer.2024; 25(4): e181.     CrossRef
  • Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis
    Yongming Wu, Wenpeng Song, Denian Wang, Junke Chang, Yan Wang, Jie Tian, Sicheng Zhou, Yingxian Dong, Jing Zhou, Jue Li, Ziyi Zhao, Guowei Che
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer
    Pengfei Zhang, Wei Chen, Kewei Zhao, Xiaowen Qiu, Tao Li, Xingzhuang Zhu, Peng Sun, Chunsheng Wang, Yipeng Song
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors
    Jixia Han, Qi Song, Feng Guo, Rui Du, Henghu Fang, Jingbo Kang, Zejun Lu
    Nuclear Medicine Communications.2022;[Epub]     CrossRef
  • Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer
    Yu-Sen Huang, Jenny Ling-Yu Chen, Hsin-Ming Chen, Li-Hao Yeh, Jin-Yuan Shih, Ruoh-Fang Yen, Yeun-Chung Chang
    BMC Cancer.2021;[Epub]     CrossRef
  • Potential role of functional imaging in predicting outcome for patients treated with carbon ion therapy: a review
    Giulia Riva, Sara Imparato, Giovanni Savietto, Mattia Pecorilla, Alberto Iannalfi, Amelia Barcellini, Sara Ronchi, Maria Rosaria Fiore, Chiara Paganelli, Giulia Buizza, Mario Ciocca, Guido Baroni, Lorenzo Preda, Ester Orlandi
    The British Journal of Radiology.2021;[Epub]     CrossRef
  • Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy
    Jin Meng, Emmanuel Deshayes, Li Zhang, Wei Shi, Xiaomeng Zhang, Xingxing Chen, Xin Mei, Jinli Ma, Yizhou Jiang, Jiong Wu, Zhimin Shao, Xiaoli Yu, Zhaozhi Yang, Xiaomao Guo
    Molecular Therapy - Oncolytics.2021; 23: 412.     CrossRef
  • Parámetros cuantitativos de la PET/TC con 18F-FDG como factores pronósticos en el cáncer de pulmón localizado e inoperable
    J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M. Moreno, A. Martínez, P. Jiménez, A. Cobo
    Revista Española de Medicina Nuclear e Imagen Molecular.2020; 39(6): 353.     CrossRef
  • 18F-FDG PET/CT quantitative parameters as prognostic factors in localized and inoperable lung cancer
    J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M Moreno, A. Martínez, P. Jiménez, A. Cobo
    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2020; 39(6): 353.     CrossRef
  • 7,307 View
  • 133 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
Development of Protocol for Korean Lung Cancer Screening Project (K-LUCAS) to Evaluate Effectiveness and Feasibility to Implement National Cancer Screening Program
Jaeho Lee, Juntae Lim, Yeol Kim, Hyae Young Kim, Jin Mo Goo, Choon-Taek Lee, Seung Hun Jang, Won-Chul Lee, Chan Wha Lee, Jin Young An, Ki Dong Ko, Min Ki Lee, Kui Son Choi, Boyoung Park, Duk Hyoung Lee
Cancer Res Treat. 2019;51(4):1285-1294.   Published online February 19, 2019
DOI: https://doi.org/10.4143/crt.2018.464
AbstractAbstract PDFPubReaderePub
Purpose
To reduce lung cancer mortality, lung cancer screening was recommended using low-dose computed tomography (LDCT) to high-risk population. A protocol for multicenter lung cancer screening pilot project was developed to evaluate the effectiveness and feasibility of lung cancer screening to implement National Cancer Screening Program in Korea.
Materials and Methods
Multidisciplinary expert committee was comprised to develop a standardized protocol for Korean Lung Cancer Screening Project (K-LUCAS). K-LUCAS is a population-based single arm trial that targets high-risk population aged 55-74 years with at least 30 pack-year smoking history. LDCT results are reported by Lung-RADS suggested by American Radiology Society. Network-based system using computer-aided detection program is prepared to assist reducing diagnostic errors. Smoking cessation counselling is provided to all currently smoking participants. A small pilot test was conducted to check the feasibility and compliance of the protocols for K-LUCAS.
Results
In pilot test, 256 were participated. The average age of participants was 63.2 years and only three participants (1.2%) were female. The participants had a smoking history of 40.5 pack-year on average and 53.9% were current smokers. Among them, 86.3% had willing to participate in lung cancer screening again. The average willingness to quit smoking among current smokers was 12.7% higher than before screening. In Lung-RADS reports, 10 (3.9%) were grade 3 and nine (3.5%) were grade 4. One participant was diagnosed as lung cancer.
Conclusion
The protocol developed by this study is assessed to be feasible to perform K-LUCAS in multicenter nationwide scale.

Citations

Citations to this article as recorded by  
  • Gender Disparities and Lung Cancer Screening Outcomes Among Individuals Who Have Never Smoked
    Yeon Wook Kim, Dong-Hyun Joo, So Yeon Kim, Young Sik Park, Sowon Jang, Jong Hyuk Lee, Gerard A. Silvestri, Marjolein A. Heuvelmans, Jihang Kim, Hyeontaek Hwang, Choon-Taek Lee
    JAMA Network Open.2025; 8(1): e2454057.     CrossRef
  • Factors influencing the intention for lung cancer screening in high-risk populations for lung cancer
    Mi-Kyoung Cho, Yoon Hee Cho
    Asia-Pacific Journal of Oncology Nursing.2024; 11(1): 100332.     CrossRef
  • Strategies to Improve Smoking Cessation for Participants in Lung Cancer Screening Program: Analysis of Factors Associated with Smoking Cessation in Korean Lung Cancer Screening Project (K-LUCAS)
    Yeol Kim, Jaeho Lee, Eunju Lee, Juntae Lim, Yonghyun Kim, Choon-Taek Lee, Seung Hun Jang, Yu-Jin Paek, Won-Chul Lee, Chan Wha Lee, Hyae Young Kim, Jin Mo Goo, Kui Son Choi, Boyoung Park, Duk Hyoung Lee, Hong Gwan Seo
    Cancer Research and Treatment.2024; 56(1): 92.     CrossRef
  • Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
    Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
    Cancer Medicine.2024;[Epub]     CrossRef
  • Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016
    Sangwon Lee, Eun Hye Park, Bo Yun Jang, Ye Ji Kang, Kyu-Won Jung, Hyo Soung Cha, Kui Son Choi
    Scientific Reports.2024;[Epub]     CrossRef
  • Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study
    So Yeon Kim, Gerard A. Silvestri, Yeon Wook Kim, Roger Y. Kim, Sang-Won Um, Yunjoo Im, Jung Hye Hwang, Seung Ho Choi, Jung Seop Eom, Kang Mo Gu, Yong-Soo Kwon, Shin Yup Lee, Hyun Woo Lee, Dong Won Park, Yeonjeong Heo, Seung Hun Jang, Kwang Yong Choi, Yeol
    Journal of Thoracic Oncology.2024;[Epub]     CrossRef
  • Lung Cancer Screening: Implementation Challenges and Health Equity Considerations For the Western Pacific Region
    Claire Nightingale, Claire Bavor, Emily Stone, Nicole M. Rankin
    JCO Global Oncology.2023;[Epub]     CrossRef
  • Lung Imaging Reporting and Data System (Lung-RADS) in Radiology: Strengths, Weaknesses and Improvement
    Gong Yong Jin
    Journal of the Korean Society of Radiology.2023; 84(1): 34.     CrossRef
  • Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020
    Sang Ah Chi, Hyeyeon Yu, Yoon-La Choi, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Dae-Ho Choi, Kyunga Kim, Hyun Ae Jung, Keunchil Park
    JAMA Network Open.2023; 6(3): e232002.     CrossRef
  • Interstitial Lung Abnormalities at CT in the Korean National Lung Cancer Screening Program: Prevalence and Deep Learning–based Texture Analysis
    Kum Ju Chae, Soyeoun Lim, Joon Beom Seo, Hye Jeon Hwang, Hyemi Choi, David Lynch, Gong Yong Jin
    Radiology.2023;[Epub]     CrossRef
  • Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard
    David R. Baldwin, Emma L. O'Dowd, Ilona Tietzova, Anna Kerpel-Fronius, Marjolein A. Heuvelmans, Annemiek Snoeckx, Haseem Ashraf, Hans-Ulrich Kauczor, Blin Nagavci, Matthijs Oudkerk, Paul Martin Putora, Witold Ryzman, Giulia Veronesi, Andrea Borondy-Kitts,
    European Respiratory Journal.2023; 61(6): 2300128.     CrossRef
  • Association of immunotoxicological indices with lung cancer biomarkers in poultry, grape, and rose farming workers
    Anju Maharjan, Ravi Gautam, Manju Acharya, JiHun Jo, DaEun Lee, Pramod Bahadur K C, Young-A Lee, Jung-Taek Kwon, HyoCher Kim, KyungRan Kim, ChangYul Kim, HyoungAh Kim, Yong Heo
    Toxicological Research.2023; 39(4): 739.     CrossRef
  • Performance of Lung-RADS in different target populations: a systematic review and meta-analysis
    Yifei Mao, Jiali Cai, Marjolein A. Heuvelmans, Rozemarijn Vliegenthart, Harry J. M. Groen, Matthijs Oudkerk, Marleen Vonder, Monique D. Dorrius, Geertruida H. de Bock
    European Radiology.2023; 34(3): 1877.     CrossRef
  • Perspectives and limitations of Lung-RADS in different target populations: the power of systematic review and meta-analysis
    Simone Vicini
    European Radiology.2023; 34(3): 1875.     CrossRef
  • The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea
    Woorim Kim, Sang Chul Lee, Woo-Ri Lee, Sungyoun Chun
    Lung Cancer.2023; 186: 107412.     CrossRef
  • Study on the Application Value of Lung-RADS in the Differential Diagnosis of Benign and Malignant Lung Nodules
    ·马木提 依力夏提
    Advances in Clinical Medicine.2023; 13(12): 20190.     CrossRef
  • Lung Cancer Screening with Low-Dose Chest Computed Tomography
    Yeon Wook Kim
    The Korean Journal of Medicine.2022; 97(1): 42.     CrossRef
  • Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project
    Juyoung Kim, Bogeum Cho, Seon-Ha Kim, Chang-Min Choi, Yeol Kim, Min-Woo Jo
    Cancer Research and Treatment.2022; 54(3): 728.     CrossRef
  • Potential Overdiagnosis with CT Lung Cancer Screening in Taiwanese Female: Status in South Korea
    Jin Mo Goo, Kyu-Won Jung, Hyae Young Kim, Yeol Kim
    Korean Journal of Radiology.2022; 23(6): 571.     CrossRef
  • Lung Cancer Patients’ Characteristics and Comorbidities Using the Korean National Hospital Discharge In-depth Injury Survey Data
    Kyunghee Lee, Sunghong Kang, Jieun Hwang
    Journal of Epidemiology and Global Health.2022; 12(3): 258.     CrossRef
  • Reduced Cancer Screening Due to Lockdowns of the COVID-19 Pandemic: Reviewing Impacts and Ways to Counteract the Impacts
    Tuan Luu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Determination of the optimum definition of growth evaluation for indeterminate pulmonary nodules detected in lung cancer screening
    Jong Hyuk Lee, Eui Jin Hwang, Woo Hyeon Lim, Jin Mo Goo, Paul Cronin
    PLOS ONE.2022; 17(9): e0274583.     CrossRef
  • Implementation of the cloud-based computerized interpretation system in a nationwide lung cancer screening with low-dose CT: comparison with the conventional reading system
    Eui Jin Hwang, Jin Mo Goo, Hyae Young Kim, Jaeyoun Yi, Soon Ho Yoon, Yeol Kim
    European Radiology.2021; 31(1): 475.     CrossRef
  • Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives
    Matthijs Oudkerk, ShiYuan Liu, Marjolein A. Heuvelmans, Joan E. Walter, John K. Field
    Nature Reviews Clinical Oncology.2021; 18(3): 135.     CrossRef
  • Variability in interpretation of low-dose chest CT using computerized assessment in a nationwide lung cancer screening program: comparison of prospective reading at individual institutions and retrospective central reading
    Eui Jin Hwang, Jin Mo Goo, Hyae Young Kim, Soon Ho Yoon, Gong Yong Jin, Jaeyoun Yi, Yeol Kim
    European Radiology.2021; 31(5): 2845.     CrossRef
  • External validation and comparison of the Brock model and Lung-RADS for the baseline lung cancer CT screening using data from the Korean Lung Cancer Screening Project
    Hyungjin Kim, Hyae Young Kim, Jin Mo Goo, Yeol Kim
    European Radiology.2021; 31(6): 4004.     CrossRef
  • Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation
    Jacob Sands, Martin C. Tammemägi, Sebastien Couraud, David R. Baldwin, Andrea Borondy-Kitts, David Yankelevitz, Jennifer Lewis, Fred Grannis, Hans-Ulrich Kauczor, Oyunbileg von Stackelberg, Lecia Sequist, Ugo Pastorino, Brady McKee
    Journal of Thoracic Oncology.2021; 16(1): 37.     CrossRef
  • Optimum diameter threshold for lung nodules at baseline lung cancer screening with low-dose chest CT: exploration of results from the Korean Lung Cancer Screening Project
    Eui Jin Hwang, Jin Mo Goo, Hyae Young Kim, Jaeyoun Yi, Yeol Kim
    European Radiology.2021; 31(9): 7202.     CrossRef
  • Effectiveness of radiologist training in improving reader agreement for Lung-RADS 4X categorization
    Hyungjin Kim, Jin Mo Goo, Tae Jung Kim, Hyae Young Kim, Guanmin Gu, Bomi Gil, Wooil Kim, Seon Young Park, Junghoan Park, Juil Park, Harkhoon Park, Wonkyu Song, Kyung Eun Shin, Jiseon Oh, Sung Hyun Yoon, Sanghyup Lee, Youkyung Lee, Woo Hyeon Lim, Won Gi Je
    European Radiology.2021; 31(11): 8147.     CrossRef
  • Contemporary issues in the implementation of lung cancer screening
    Stephen Lam, Martin Tammemagi
    European Respiratory Review.2021; 30(161): 200288.     CrossRef
  • Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis
    John K. Field, Daniel Vulkan, Michael P.A. Davies, David R. Baldwin, Kate E. Brain, Anand Devaraj, Tim Eisen, John Gosney, Beverley A. Green, John A. Holemans, Terry Kavanagh, Keith M. Kerr, Martin Ledson, Kate J. Lifford, Fiona E. McRonald, Arjun Nair, R
    The Lancet Regional Health - Europe.2021; 10: 100179.     CrossRef
  • Assisted versus Manual Interpretation of Low-Dose CT Scans for Lung Cancer Screening: Impact on Lung-RADS Agreement
    Colin Jacobs, Anton Schreuder, Sarah J. van Riel, Ernst Th. Scholten, Rianne Wittenberg, Mathilde M. Winkler Wille, Bartjan de Hoop, Ralf Sprengers, Onno M. Mets, Bram Geurts, Mathias Prokop, Cornelia Schaefer-Prokop, Bram van Ginneken
    Radiology: Imaging Cancer.2021; 3(5): e200160.     CrossRef
  • Coronary artery calcium severity grading on non-ECG-gated low-dose chest computed tomography: a multiple-observer study in a nationwide lung cancer screening registry
    Young Joo Suh, Ji Won Lee, So Youn Shin, Jin Mo Goo, Yeol Kim, Hwan Seok Yong
    European Radiology.2020; 30(7): 3684.     CrossRef
  • Korean National Lung Cancer Screening
    Seung Hun Jang
    The Korean Journal of Medicine.2020; 95(2): 95.     CrossRef
  • Lung Cancer CT Screening and Lung-RADS in a Tuberculosis-endemic Country: The Korean Lung Cancer Screening Project (K-LUCAS)
    Hyungjin Kim, Hyae Young Kim, Jin Mo Goo, Yeol Kim
    Radiology.2020; 296(1): 181.     CrossRef
  • Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society
    Hiroto Hatabu, Gary M Hunninghake, Luca Richeldi, Kevin K Brown, Athol U Wells, Martine Remy-Jardin, Johny Verschakelen, Andrew G Nicholson, Mary B Beasley, David C Christiani, Raúl San José Estépar, Joon Beom Seo, Takeshi Johkoh, Nicola Sverzellati, Chri
    The Lancet Respiratory Medicine.2020; 8(7): 726.     CrossRef
  • Milestones towards lung cancer screening implementation
    M. Silva, G. Milanese, H.-U. Kauczor, M.-P. Revel, N. Sverzellati
    Clinical Radiology.2020; 75(12): 881.     CrossRef
  • Evidence of National Lung Cancer Screening Program in Korea
    Yeol Kim
    Korean Journal of Health Promotion.2019; 19(4): 161.     CrossRef
  • 11,256 View
  • 368 Download
  • 38 Web of Science
  • 38 Crossref
Close layer
Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma
Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang
Cancer Res Treat. 2019;51(1):24-33.   Published online February 5, 2018
DOI: https://doi.org/10.4143/crt.2017.404
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the impact of contrast enhanced pancreatic magnetic resonance imaging (MRI) in resectability and prognosis evaluation after staging computed tomography (CT) in patients with pancreatic ductal adenocarcinoma (PDA).
Materials and Methods
From January 2005 to December 2012, 298 patients were diagnosed to have potentially resectable stage PDA on CT. Patients were divided into CT+MR (patients underwent both CT and MRI; n=216) and CT only groups (n=82). Changes in resectability staging in the CT+MR group were evaluated. The overall survival was compared between the two groups. The recurrence-free survival and median time to liver metastasis after curative surgery were compared between the two groups.
Results
Staging was changed from resectable on CT to unresectable state on MRI in 14.4% of (31 of 216 patients) patients of the CT+MR group. The overall survival and recurrence-free survival rates were not significantly different between the two groups (p=0.162 and p=0.721, respectively). The median time to liver metastases after curative surgery in the CT+MR group (9.9 months) was significantly longer than that in the CT group (4.2 months) (p=0.011).
Conclusion
Additional MRI resulted in changes of resectability and treatment modifications in a significant proportion of patients who have potentially resectable state at CT and in prolonged time to liver metastases in patients after curative surgery. Additional MRI to standard staging CT can be recommended for surgical candidates of PDA.

Citations

Citations to this article as recorded by  
  • Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
    Doaa Bugazia, Ebtesam Al-Najjar, Abdullah Esmail, Saifudeen Abdelrahim, Karen Abboud, Adham Abdelrahim, Godsfavour Umoru, Hashem A. Rayyan, Ala Abudayyeh, Ala-Eddin Al Moustafa, Maen Abdelrahim
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
    Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2024; 62(10): e874.     CrossRef
  • S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
    Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2024; 62(10): 1724.     CrossRef
  • Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
    Felix G. Gassert, Sebastian Ziegelmayer, Johanna Luitjens, Florian T. Gassert, Fabian Tollens, Johann Rink, Marcus R. Makowski, Johannes Rübenthaler, Matthias F. Froelich
    European Radiology.2022; 32(4): 2448.     CrossRef
  • Diagnostik beim Pankreaskarzinom – Update in der neuen Leitlinie
    L. Grenacher, M. Juchems, A. G. Schreyer, J. Wessling, K. I. Ringe, W. Uhl, J. Mayerle, T. Seufferlein
    Der Chirurg.2022; 93(5): 429.     CrossRef
  • Pancreatic adenocarcinoma: imaging techniques for diagnosis and management
    Jawaad Farrukh, Ravivarma Balasubramaniam, Anitha James, Sharan S Wadhwani, Raneem Albazaz
    British Journal of Hospital Medicine.2022; 83(5): 1.     CrossRef
  • S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL
    Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2022; 60(06): 991.     CrossRef
  • S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
    Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2022; 60(11): e812.     CrossRef
  • The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma
    Hyungjin Rhee, Mi-Suk Park
    Korean Journal of Radiology.2021; 22(1): 23.     CrossRef
  • A Comparative Study of Survivor Outcomes between Preoperative Evaluation Using CT Alone and Combined CT and MRI in Patients with Pancreatic Ductal Adenocarcinoma
    Ji Eun Lee, Seong Hyun Kim, Soon Jin Lee, Seo-Youn Choi, Sunyoung Lee, Bo Ra Lee
    Journal of the Korean Society of Radiology.2021; 82(3): 638.     CrossRef
  • СT and MRI in the assessment of resectable and borderline resectable pancreatic tumors
    A. V. Kudryavtseva, S. S. Bagnenko, I. I. Dzidzawa, I. S. Zheleznyak, G. E. Trufanov, V. V. Ryazanov, V. A. Krasovskaya, A. B. Kotiv, A. D. Kazakov
    Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2021; 26(1): 34.     CrossRef
  • European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer
    Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, Marc Beishon, Pierluigi Bonomo, Graça Braz, Filippo de Braud, Thomas Brunner, Giulia Martina Cavestro, Mirjam Crul, Maria Die Trill, Piero Ferollà, Ken Herrmann, Eva Karamitopoulou, Cindy Neuzillet
    Cancer Treatment Reviews.2021; 99: 102208.     CrossRef
  • ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial
    Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Masayuki Sho, Masaji Tani, Ippei Matsumoto, Suguru Yamada, Ryosuke Amano, Hirochika Toyama, Yo-ichi Yamashita, Takeshi Gocho, Kazuto Shibuya, Minako Nagai, Hiromitsu Maehira, Keiko Kamei, Go Ohira, Yoshihiro Shi
    Trials.2021;[Epub]     CrossRef
  • Management of Primary Squamous Cell Carcinoma of the Pancreas: A Case Report
    Danling Guo, Chao Chen, Sangying Lv, Guanzuan Wu, Wei Shi, Huaifeng Li, Hongjie Hu
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC
    Min Woo Kim, Hani Koh, Jee Ye Kim, Suji Lee, Hyojung Lee, Young Kim, Ho Kyoung Hwang, Seung Il Kim
    International Journal of Molecular Sciences.2021; 22(24): 13621.     CrossRef
  • Imaging and Management of Pancreatic Cancer
    Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
    Seminars in Ultrasound, CT and MRI.2020; 41(2): 139.     CrossRef
  • DUPLICATE: Imaging and Management of Pancreatic Cancer
    Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
    Seminars in Ultrasound, CT and MRI.2019;[Epub]     CrossRef
  • 10,738 View
  • 316 Download
  • 18 Web of Science
  • 17 Crossref
Close layer
Lung Cancer Screening with Low-Dose CT in Female Never Smokers: Retrospective Cohort Study with Long-term National Data Follow-up
Hyae Young Kim, Kyu-Won Jung, Kun Young Lim, Soo-Hyun Lee, Jae Kwan Jun, Jeongseon Kim, Bin Hwangbo, Jin Soo Lee
Cancer Res Treat. 2018;50(3):748-756.   Published online July 17, 2017
DOI: https://doi.org/10.4143/crt.2017.312
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Because of growing concerns about lung cancer in female never smokers, chest low-dose computed tomography (LDCT) screening is often performed although it has never shown clinical benefits. We examinewhether or not female never smokers really need annual LDCT screening when the initial LDCT showed negative findings.
Materials and Methods
This retrospective cohort study included 4,365 female never smokers aged 40 to 79 years who performed initial LDCT from Aug 2002 to Dec 2007. Lung cancer diagnosis was identified from the Korea Central Cancer Registry Database registered until December 31, 2013. We calculated the incidence, cumulative probability, and standardized incidence ratio (SIR) of lung cancer by Lung Imaging Reporting and Data System (Lung-RADS) categories showed on initial LDCT.
Results
After median follow-up of 9.69 years, 22 (0.5%) had lung cancer. Lung cancer incidence for Lung-RADS category 4 was 1,848.4 (95% confidence interval [CI], 1,132.4 to 3,017.2) per 100,000 person-years and 16.4 (95% CI, 7.4 to 36.4) for categories 1, 2, and 3 combined. The cumulative probability of lung cancer for category 4 was 10.6% at 5 years and 14.8% at 10 years while they were 0.07% and 0.17% when categories 1, 2, and 3 were combined. The SIR for subjects with category 4 was 43.80 (95% CI, 25.03 to 71.14), which was much higher than 0.47 (95% CI, 0.17 to 1.02) for categories 1, 2, and 3 combined.
Conclusion
Considering the low risk of lung cancer development in female never smokers, it seems unnecessary to repeat annual LDCT screening for at least 5 years or even longer unless the initial LDCT showed Lung-RADS category 4 findings.

Citations

Citations to this article as recorded by  
  • Lung cancer screening for never smokers: current evidence and future directions
    Kay Choong See
    Singapore Medical Journal.2024;[Epub]     CrossRef
  • Cooking oil fume exposure and Lung-RADS distribution among school cafeteria workers of South Korea
    Minjun Kim, Yangho Kim, A Ram Kim, Woon Jung Kwon, Soyeoun Lim, Woojin Kim, Cheolin Yoo
    Annals of Occupational and Environmental Medicine.2024;[Epub]     CrossRef
  • Distribution of Solid Lung Nodules Presence and Size by Age and Sex in a Northern European Nonsmoking Population
    Jiali Cai, Marleen Vonder, Gert Jan Pelgrim, Mieneke Rook, Gerdien Kramer, Harry J.M. Groen, Geertruida H. de Bock, Rozemarijn Vliegenthart
    Radiology.2024;[Epub]     CrossRef
  • Low Dose Computed Tomography for Lung Cancer Screening in Tuberculosis Endemic Countries: A Systematic Review and Meta-Analysis
    Vikram Damaraju, Juhu Kiran Krushna Karri, Gayathri Gandrakota, Yamini Marimuthu, Adimulam Ganga Ravindra, Rajeev Aravindakshan, Navneet Singh
    Journal of Thoracic Oncology.2024;[Epub]     CrossRef
  • Toward More Effective Lung Cancer Risk Stratification to Empower Screening Programs for the Asian Nonsmoking Population
    Fu-Zong Wu, Yeun-Chung Chang
    Journal of the American College of Radiology.2023; 20(2): 156.     CrossRef
  • ACR Appropriateness Criteria® Lung Cancer Screening: 2022 Update
    Kim L. Sandler, Travis S. Henry, Arya Amini, Saeed Elojeimy, Aine Marie Kelly, Christopher T. Kuzniewski, Elizabeth Lee, Maria D. Martin, Michael F. Morris, Neeraja B. Peterson, Constantine A. Raptis, Gerard A. Silvestri, Arlene Sirajuddin, Betty C. Tong,
    Journal of the American College of Radiology.2023; 20(5): S94.     CrossRef
  • Performance of Lung-RADS in different target populations: a systematic review and meta-analysis
    Yifei Mao, Jiali Cai, Marjolein A. Heuvelmans, Rozemarijn Vliegenthart, Harry J. M. Groen, Matthijs Oudkerk, Marleen Vonder, Monique D. Dorrius, Geertruida H. de Bock
    European Radiology.2023; 34(3): 1877.     CrossRef
  • Preoperative computed tomography-guided patent blue localization for pulmonary nodules
    Po-Chih Chang, Shah-Hwa Chou, Che-Yu Chuang, I-Hsiao Yang, Yu-Wei Liu, Ming-Cheng Shi, Reu-Sheng Sheu, Ting-Wei Chang
    Formosan Journal of Surgery.2022; 55(3): 102.     CrossRef
  • Lung cancer screening in never-smokers: facts and remaining issues
    Maurizio V. Infante, Giuseppe Cardillo
    European Respiratory Journal.2020; 56(5): 2002949.     CrossRef
  • Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers
    Yeon Wook Kim, Hye-Rin Kang, Byoung Soo Kwon, Sung Yoon Lim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
    European Respiratory Journal.2020; 56(5): 2000177.     CrossRef
  • Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model
    Li-Hsin Chien, Chung-Hsing Chen, Tzu-Yu Chen, Gee-Chen Chang, Ying-Huang Tsai, Chin-Fu Hsiao, Kuan-Yu Chen, Wu-Chou Su, Wen-Chang Wang, Ming-Shyan Huang, Yuh-Min Chen, Chih-Yi Chen, Sheng-Kai Liang, Chung-Yu Chen, Chih-Liang Wang, Mei-Hsuan Lee, Ren-Hua C
    Cancer Epidemiology, Biomarkers & Prevention.2020; 29(2): 452.     CrossRef
  • Role of Low-Dose Computerized Tomography in Lung Cancer Screening among Never-Smokers
    Hye-Rin Kang, Jun Yeun Cho, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
    Journal of Thoracic Oncology.2019; 14(3): 436.     CrossRef
  • Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018
    Haval Balata, Kwun M. Fong, Lizza E. Hendriks, Stephen Lam, Jamie S. Ostroff, Nir Peled, Ning Wu, Charu Aggarwal
    Journal of Thoracic Oncology.2019; 14(9): 1513.     CrossRef
  • 14,615 View
  • 357 Download
  • 16 Web of Science
  • 13 Crossref
Close layer
Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery
Soo Kyung Ahn, Min Kyoon Kim, Jongjin Kim, Eunshin Lee, Tae-Kyung Yoo, Han-Byoel Lee, Young Joon Kang, Jisun Kim, Hyeong-Gon Moon, Jung Min Chang, Nariya Cho, Woo Kyung Moon, In Ae Park, Dong-Young Noh, Wonshik Han
Cancer Res Treat. 2017;49(4):1088-1096.   Published online January 25, 2017
DOI: https://doi.org/10.4143/crt.2016.473
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The American College of Surgeons Oncology Group Z0011 trial reported that complete dissection of axillary lymph nodes (ALNs) may not be warranted in women with clinical T1-T2 tumors and one or two involved ALNs who were undergoing lumpectomy plus radiation followed by systemic therapy. The present study was conducted to identify preoperative imaging predictors of ≥ 3 ALNs.
Materials and Methods
The training set consisted of 1,917 patients with clinical T1-T2 and node negative invasive breast cancer. Factors associated with ≥ 3 involved ALNs were evaluated by logistic regression analysis. The validation set consisted of 378 independent patients. The nomogram was applied prospectively to 512 patients who met the Z0011 criteria.
Results
Of the 1,917 patients, 204 (10.6%) had ≥ 3 positive nodes. Multivariate analysis showed that involvement of ≥ 3 nodes was significantly associated with ultrasonographic and chest computed tomography findings of suspicious ALNs (p < 0.001 each). These two imaging criteria, plus patient age, were used to develop a nomogram calculating the probability of involvement of ≥ 3 ALNs. The areas under the receiver operating characteristic curve of the nomogram were 0.852 (95% confidence interval [CI], 0.820 to 0.883) for the training set and 0.896 (95% CI, 0.836 to 0.957) for the validation set. Prospective application of the nomogram showed that 60 of 512 patients (11.7%) had scores above the cut-off. Application of the nomogram reduced operation time and cost, with a very low re-operation rate (1.6%).
Conclusion
Patients likely to have ≥ 3 positive ALNs could be identified by preoperative imaging. The nomogram was helpful in selective intraoperative examination of sentinel lymph nodes.

Citations

Citations to this article as recorded by  
  • Predicting three or more metastatic nodes using contrast-enhanced lymphatic US findings in early breast cancer
    Zihan Niu, Yunxia Hao, Yuanjing Gao, Jing Zhang, Mengsu Xiao, Feng Mao, Yidong Zhou, Ligang Cui, Yuxin Jiang, Qingli Zhu
    Insights into Imaging.2024;[Epub]     CrossRef
  • Individualized prediction of non-sentinel lymph node metastasis in Chinese breast cancer patients with ≥ 3 positive sentinel lymph nodes based on machine-learning algorithms
    Xiangli Xie, Yutong Fang, Lifang He, Zexiao Chen, Chunfa Chen, Huancheng Zeng, Bingfeng Chen, Guangsheng Huang, Cuiping Guo, Qunchen Zhang, Jundong Wu
    BMC Cancer.2024;[Epub]     CrossRef
  • Gail model and fifth edition of ultrasound BI‐RADS help predict axillary lymph node metastasis in breast cancer—A multicenter prospective study
    Lu‐Ying Gao, Hai‐Tao Ran, You‐Bin Deng, Bao‐Ming Luo, Ping Zhou, Wu Chen, Yu‐Hong Zhang, Jian‐Chu Li, Hong‐Yan Wang, Yu‐Xin Jiang
    Asia-Pacific Journal of Clinical Oncology.2023;[Epub]     CrossRef
  • Nomogram based on multiparametric analysis of early‐stage breast cancer: Prediction of high burden metastatic axillary lymph nodes
    Ling Li, Jing Zhao, Yu Zhang, Zhanyu Pan, Jin Zhang
    Thoracic Cancer.2023; 14(35): 3465.     CrossRef
  • Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer
    Jieying Chen, Xiaolian Su, Tingting Xu, Qifeng Luo, Lin Zhang, Guangyu Tang
    Future Oncology.2022; 18(15): 1849.     CrossRef
  • ACR Appropriateness Criteria® Imaging of the Axilla
    Huong T. Le-Petross, Priscilla J. Slanetz, Alana A. Lewin, Jean Bao, Elizabeth H. Dibble, Mehra Golshan, Jessica H. Hayward, Charlotte D. Kubicky, A. Marilyn Leitch, Mary S. Newell, Christine Prifti, Matthew F. Sanford, John R. Scheel, Richard E. Sharpe,
    Journal of the American College of Radiology.2022; 19(5): S87.     CrossRef
  • Avoiding unnecessary intraoperative sentinel lymph node frozen section biopsy of patients with early breast cancer
    Jongwon Kang, Tae-Kyung Yoo, Ahwon Lee, Jun Kang, Chang Ik Yoon, Bong Joo Kang, Sung Hun Kim, Woo Chan Park
    Annals of Surgical Treatment and Research.2022; 102(5): 241.     CrossRef
  • A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery
    Young-Joon Kang, Jung Hyun Park, Young Wook Ju, Kyoung-Eun Kim, Yumi Kim, Eunshin Lee, Han-Byoel Lee, Dong-Young Noh, Wonshik Han
    Scientific Reports.2022;[Epub]     CrossRef
  • Accurate Evaluation of Feature Contributions for Sentinel Lymph Node Status Classification in Breast Cancer
    Angela Lombardi, Nicola Amoroso, Loredana Bellantuono, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Daniele La Forgia, Vito Lorusso, Alfonso Monaco, Sabina Tangaro, Francesco Alfredo Zito, Roberto Bellotti, Raffaella Massafra
    Applied Sciences.2022; 12(14): 7227.     CrossRef
  • Is Routine Intraoperative Frozen Section Analysis of Sentinel Lymph Nodes Necessary in Every Early-Stage Breast Cancer?
    Bhoowit Lerttiendamrong, Nattanan Treeratanapun, Voranaddha Vacharathit, Kasaya Tantiphlachiva, Phuphat Vongwattanakit, Sopark Manasnayakorn, Mawin Vongsaisuwon
    Breast Cancer: Targets and Therapy.2022; Volume 14: 281.     CrossRef
  • Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer
    Sheng-Kai Geng, Shao-Mei Fu, Hong-Wei Zhang, Yi-Peng Fu
    BMC Cancer.2022;[Epub]     CrossRef
  • Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI
    Su Min Ha, Jung Min Chang, Soo-Yeon Kim, Su Hyun Lee, Eun Sil Kim, Yeon Soo Kim, Nariya Cho, Woo Kyung Moon
    Breast Cancer Research and Treatment.2021; 186(2): 463.     CrossRef
  • Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study
    Annarita Fanizzi, Domenico Pomarico, Angelo Paradiso, Samantha Bove, Sergio Diotaiuti, Vittorio Didonna, Francesco Giotta, Daniele La Forgia, Agnese Latorre, Maria Irene Pastena, Pasquale Tamborra, Alfredo Zito, Vito Lorusso, Raffaella Massafra
    Cancers.2021; 13(2): 352.     CrossRef
  • Sentinel Lymph Node Metastasis on Clinically Negative Patients: Preliminary Results of a Machine Learning Model Based on Histopathological Features
    Annarita Fanizzi, Vito Lorusso, Albino Biafora, Samantha Bove, Maria Colomba Comes, Cristian Cristofaro, Maria Digennaro, Vittorio Didonna, Daniele La Forgia, Annalisa Nardone, Domenico Pomarico, Pasquale Tamborra, Alfredo Zito, Angelo Virgilio Paradiso,
    Applied Sciences.2021; 11(21): 10372.     CrossRef
  • The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011
    Eunjung Kong, Jungeun Choi
    Nuclear Medicine Communications.2021; 42(12): 1369.     CrossRef
  • Clinical Value of Axillary Ultrasonography in Breast Cancer with Lymph Node Metastases
    Jung Ho Park, Hyun Ryung Kim, Sanghwa Kim, Young Ah Lim, Kyoonsoon Jung, Lee Su Kim
    Journal of Surgical Ultrasound.2021; 8(2): 41.     CrossRef
  • Can a machine-learning model improve the prediction of nodal stage after a positive sentinel lymph node biopsy in breast cancer?
    V. Madekivi, P. Boström, A. Karlsson, R. Aaltonen, E. Salminen
    Acta Oncologica.2020; 59(6): 689.     CrossRef
  • External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
    Antonio Piñero-Madrona, Francisco Ripoll-Orts, José Ignacio Sánchez-Méndez, Asunción Chaves-Benito, Maximiliano Rodrigo Gómez-de la Bárcena, Ana Calatrava-Fons, Salomón Menjón-Beltrán, Vicente Peg-Cámara
    Breast Cancer Research and Treatment.2020; 181(2): 339.     CrossRef
  • Axillary Nodal Evaluation in Breast Cancer: State of the Art
    Jung Min Chang, Jessica W. T. Leung, Linda Moy, Su Min Ha, Woo Kyung Moon
    Radiology.2020; 295(3): 500.     CrossRef
  • Can We Identify or Exclude Extensive Axillary Nodal Involvement in Breast Cancer Patients Preoperatively?
    Martijn Leenders, Gaëlle Kramer, Kamar Belghazi, Katya Duvivier, Petrousjka van den Tol, Hermien Schreurs
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • Computer-aided prediction model for axillary lymph node metastasis in breast cancer using tumor morphological and textural features on ultrasound
    Woo Kyung Moon, I-Ling Chen, Ann Yi, Min Sun Bae, Sung Ui Shin, Ruey-Feng Chang
    Computer Methods and Programs in Biomedicine.2018; 162: 129.     CrossRef
  • The Evolution of the Current Indications for Sentinel Lymph Node Biopsy in Breast Cancer
    Sofia E Triantafillidou
    Hellenic Journal of Surgery.2018; 90(4): 186.     CrossRef
  • Axillary Lymph Node to Primary Breast Tumor Standardized Uptake Value Ratio from FDG-PET/CT Imaging for Predicting the Necessity for Nodal Dissection in Primary Breast Tumors
    Han-kyul Shin, Min Kyoon Kim, Sung Jun Park, Ju Won Seok, Hee-Chul Shin
    Journal of Breast Disease.2017; 5(2): 76.     CrossRef
  • 10,695 View
  • 356 Download
  • 21 Web of Science
  • 23 Crossref
Close layer
Detecting Metastatic Bladder Cancer Using 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography
Hakan Öztürk
Cancer Res Treat. 2015;47(4):834-843.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.157
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to retrospectively investigate the contribution of 18F-fluorodeoxyglucose- positron emission tomography/computed tomography (18F-FDG-PET/CT) to detection of metastatic bladder cancer. Materials and Methods The present study included 79 patients (69 men and 10 women) undergoing 18F-FDGPET/ CT upon suspicion of metastatic bladder cancer between July 2007 and April 2013. The mean age was 66.1 years with a standard deviation of 10.7 years (range, 21 to 85 years). Patients were required to fast for 6 hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 hour after intravenous injection of 555 MBq of 18F-FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up. Results The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-FDG-PET/CT were 89%, 78%, 90%, 75%, and 86%, respectively. Conclusion 18F-FDG-PET/CT can detect metastases with high sensitivity and positive predictive values in patients with metastatic bladder carcinoma.

Citations

Citations to this article as recorded by  
  • Radiotherapy in metastatic bladder cancer
    Sophie Ashley, Ananya Choudhury, Peter Hoskin, YeePei Song, Priyamvada Maitre
    World Journal of Urology.2024;[Epub]     CrossRef
  • PET Imaging in Bladder Cancer: An Update and Future Direction
    Jules Zhang-Yin, Antoine Girard, Etienne Marchal, Thierry Lebret, Marie Homo Seban, Marine Uhl, Marc Bertaux
    Pharmaceuticals.2023; 16(4): 606.     CrossRef
  • Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy
    Olivier Fitoussi, Jean Baptiste Roche, Julien Riviere, Hervé Wallerand, Jean Eude Poulain, Pierre Gordien, Sigolène Galland, Bénédicte Henriques, Camille Dupin, Muriel Vincent, Thomas Kuratle, Mo Saffarini, Sonia Ramos-Pascual
    Urologia Internationalis.2023; 107(3): 239.     CrossRef
  • PET/CT in Bladder Cancer: An Update
    Kirsten Bouchelouche
    Seminars in Nuclear Medicine.2022; 52(4): 475.     CrossRef
  • Quantitative positron emission tomography imaging in the presence of iodinated contrast media using electron density quantifications from dual‐energy computed tomography
    Nadav Shapira, Joshua Scheuermann, Amy E. Perkins, Johoon Kim, Leening P Liu, Joel S. Karp, Peter B. Noël
    Medical Physics.2021; 48(1): 273.     CrossRef
  • 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer
    Sarah M.H. Einerhand, Erik J. van Gennep, Laura S. Mertens, Kees Hendricksen, Maarten L. Donswijk, Henk G. van der Poel, Bas W.G. van Rhijn
    Current Opinion in Urology.2020; 30(5): 654.     CrossRef
  • The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma
    Antoine Girard, Helena Vila Reyes, Hiram Shaish, Jean-François Grellier, Laurent Dercle, Pierre-Yves Salaün, Olivier Delcroix, Mathieu Rouanne
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Cancers de la vessie
    A. Girard, J.F. Grellier, P.Y. Salaün
    Médecine Nucléaire.2019; 43(1): 69.     CrossRef
  • Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
    Antoine Girard, Mathieu Rouanne
    European Journal of Nuclear Medicine and Molecular Imaging.2019; 46(6): 1212.     CrossRef
  • Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study
    Fabio Zattoni, Elena Incerti, Michele Colicchia, Paolo Castellucci, Stefano Panareo, Maria Picchio, Federico Fallanca, Alberto Briganti, Marco Moschini, Andrea Gallina, Jeffrey R. Karnes, Val Lowe, Stefano Fanti, Riccardo Schiavina, Ilaria Rambaldi, Vince
    Abdominal Radiology.2018; 43(9): 2391.     CrossRef
  • The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis
    Anna Rita Cervino, Lea Cuppari, Pasquale Reccia, Marta Burei, Giorgio Saladini, Laura Evangelista
    Clinical and Translational Imaging.2018; 6(2): 77.     CrossRef
  • Pelvic Lymph Node Staging by Combined 18 F-FDG-PET/CT Imaging in Bladder Cancer Prior to Radical Cystectomy
    Renate Pichler, Tobias De Zordo, Josef Fritz, Alexander Kroiss, Friedrich Aigner, Isabel Heidegger, Irene Virgolini, Wolfgang Horninger, Christian Uprimny
    Clinical Genitourinary Cancer.2017; 15(3): e387.     CrossRef
  • Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness
    Julieta Afonso, Lúcio L. Santos, António Morais, Teresina Amaro, Adhemar Longatto-Filho, Fátima Baltazar
    Cell Cycle.2016; 15(3): 368.     CrossRef
  • The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy
    William P. Parker, Philip L. Ho, Stephen A. Boorjian, Jonathan J. Melquist, Prabin Thapa, Jeffrey M. Holzbeierlein, Igor Frank, Ashish M. Kamat, Eugene K. Lee
    World Journal of Urology.2016; 34(11): 1561.     CrossRef
  • 15,446 View
  • 100 Download
  • 19 Web of Science
  • 14 Crossref
Close layer
Case Report
Usefulness of Digital Tomosynthesis for the Detection of Airway Obstruction: A Case Report of Bronchial Carcinosarcoma
Sung-Joon Park, Ji Yung Choo, Ki Yeol Lee, Je-Hyeong Kim, Jung-Woo Choi, Suk Keu Yeom, Baek Hyun Kim
Cancer Res Treat. 2015;47(3):544-548.   Published online September 11, 2014
DOI: https://doi.org/10.4143/crt.2013.220
AbstractAbstract PDFPubReaderePub
Bronchial carcinosarcoma is a very rare malignant tumor that is composed of carcinomatous and sarcomatous elements. We describe the first case in which digital tomosynthesis was useful for the evaluation of airway obstruction by bronchial carcinosarcoma that was overlooked on initial chest radiography.

Citations

Citations to this article as recorded by  
  • A Rare Case of Tracheal Leiomyoma: Role of Digital Tomosynthesis in Diagnosis and Treatment
    Soo Won Nam, Yeon Joo Jeong, Geewon Lee, Ji Won Lee, Jung Seop Eom, Chang Hun Lee, So Min Park
    Journal of the Korean Society of Radiology.2020; 81(1): 225.     CrossRef
  • Accuracy of Digital Tomosynthesis of the Chest in Detection of Interstitial Lung Disease Comparison With Digital Chest Radiography
    Temphon Kruamak, Rachael Edwards, Stephanie Cheng, Daniel S. Hippe, Ganesh Raghu, Sudhakar N. J. Pipavath
    Journal of Computer Assisted Tomography.2019; 43(1): 109.     CrossRef
  • High‐speed slot‐scanning radiography using small‐angle tomosynthesis: Investigation of spatial resolution
    Christoph Luckner, Magdalena Herbst, Thomas Weber, Marcel Beister, Ludwig Ritschl, Steffen Kappler, Andreas Maier
    Medical Physics.2019; 46(12): 5454.     CrossRef
  • Construction of an Anthropomorphic Phantom for Use in Evaluating Pediatric Airway Digital Tomosynthesis Protocols
    Nima Kasraie, Amie Robinson, Sherwin Chan
    Radiology Research and Practice.2018; 2018: 1.     CrossRef
  • Whole-Body Clinical Applications of Digital Tomosynthesis
    Haruhiko Machida, Toshiyuki Yuhara, Mieko Tamura, Takuya Ishikawa, Etsuko Tate, Eiko Ueno, Katelyn Nye, John M. Sabol
    RadioGraphics.2016; 36(3): 735.     CrossRef
  • A comparison of digital tomosynthesis and chest radiography in evaluating airway lesions using computed tomography as a reference
    Ji Yung Choo, Ki Yeol Lee, Ami Yu, Je-Hyeong Kim, Seung Heon Lee, Jung Won Choi, Eun-Young Kang, Yu Whan Oh
    European Radiology.2016; 26(9): 3147.     CrossRef
  • 18,564 View
  • 68 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Original Article
Metabolic Burden Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Is a Prognostic Factor in Patients with Small Cell Lung Cancer
Mi-Hyun Kim, Ji Seok Lee, Jeong Ha Mok, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Seong-Jang Kim, Min Ki Lee
Cancer Res Treat. 2014;46(2):165-171.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.165
AbstractAbstract PDFPubReaderePub
Purpose

Evidence regarding the usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting the prognosis of non-small cell lung cancer is increasing. However, data on small cell lung cancer (SCLC) are scarce. The aim of this study was to evaluate the prognostic value of metabolic parameters measured using 18F-FDG PET/CT in patients with SCLC.

Materials and Methods

We conducted a retrospective review of 114 patients with pathologically proven SCLC (26 cases of limited disease and 88 cases of extensive disease) who underwent pretreatment 18F-FDG PET/CT. The maximal SUV (SUVmax) was used quantitatively for determination of FDG PET activity. The SUVmax of the primary tumor (primary SUVmax), the sum of SUVmax values of malignant lesions (SUVsum), and the mean SUVmax of malignant lesions were calculated.

Results

The patient population was subdivided using a median SUVsum value of 24.6. High SUVsum showed a significant association with known factors for poor prognosis, including higher neuron-specific enolase (p=0.010), CYFRA 21-1 (p=0.014), and extensive disease status (p=0.007). Patients with high SUVsum had significantly shorter median overall survival (6.6 months vs. 13.0 months, p<0.001) and progression-free survival (5.2 months vs. 8.0 months, p<0.001) than patients with low SUVsum. Results of multivariate analysis showed that SUVsum, chemotherapy cycles, and the response to first-line treatment were significant prognostic factors of survival. In contrast, mean SUVmax and primary SUVmax were not significant predictors of survival.

Conclusion

In this study, metabolic burden represented by SUVsum from pretreatment 18F-FDG PET/CT was an independent prognostic factor in patients with SCLC.

Citations

Citations to this article as recorded by  
  • Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer
    Mine ARAZ, Cigdem SOYDAL, Elgin ÖZKAN, Elif SEN, Demet NAK, Ozlem N. KUCUK, Ugur GÖNÜLLÜ, K. Metin KIR
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2022;[Epub]     CrossRef
  • Predictive Factors of Complete Tumor Response to First Line Chemotherapy in Patients with Extensive-stage Small Cell Lung Cancer
    Eyyüp Çavdar, Yakup İriağaç, Abdullah Sakin, Erdoğan Selçuk Şeber
    Bagcilar Medical Bulletin.2022; 7(2): 130.     CrossRef
  • Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature
    Tine Nøhr Christensen, Per Kragh Andersen, Seppo W. Langer, Barbara Malene Bjerregaard Fischer
    Diagnostics.2021; 11(2): 174.     CrossRef
  • Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC)
    Cem Mirili, Isa Burak Guney, Semra Paydas, Gulsah Seydaoglu, Tuba Korkmaz Kapukaya, Ali Ogul, Serkan Gokcay, Mahmut Buyuksimsek, Abdullah Evren Yetisir, Bilgin Karaalioglu, Mert Tohumcuoglu
    International Journal of Clinical Oncology.2019; 24(2): 168.     CrossRef
  • Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer
    Xiaozhou Yu, Yanjia Zhu, Jian Wang, Xiuyu Song, Lei Zhu, Xiaoyuan Men, Xiaofeng Li, Dong Dai, Wengui Xu
    Nuclear Medicine Communications.2017; 38(2): 193.     CrossRef
  • Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer
    Meryem Aktan, Mehmet Koc, Gul Kanyilmaz, Berrin Benli Yavuz
    Annals of Nuclear Medicine.2017; 31(6): 462.     CrossRef
  • The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer
    Soo Hyun Kwon, Seung Hyup Hyun, Joon-Kee Yoon, Young-Sil An, Young-Taek Oh, Jin-Hyuck Choi, Kwang Joo Park, Su Jin Lee
    Medicine.2016; 95(5): e2772.     CrossRef
  • First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
    A. Patnaik, L.J. Appleman, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, D.W. Rasco, G.J. Weiss, J.C. Sachdev, M. Chadha, M. Fulk, S. Ejadi, J.M. Mountz, M.T. Lotze, F.G.S. Toledo, E. Chu, M. Jeffers, C. Peña, C. Xia, S. Reif, I. Genvresse, R.K. Ramanathan
    Annals of Oncology.2016; 27(10): 1928.     CrossRef
  • A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
    Alberto A. Chiappori, Gregory A. Otterson, Afshin Dowlati, Anne M. Traynor, Leora Horn, Taofeek K. Owonikoko, Helen J. Ross, Christine L. Hann, Taher Abu Hejleh, Jorge Nieva, Xiuhua Zhao, Michael Schell, Daniel M. Sullivan
    The Oncologist.2016; 21(10): 1163.     CrossRef
  • Deriving global quantitative tumor response parameters from 18F-FDG PET-CT scans in patients with non-Hodgkin’s lymphoma
    Frederic Sampedro, Anna Domenech, Sergio Escalera, Ignasi Carrió
    Nuclear Medicine Communications.2015; 36(4): 328.     CrossRef
  • Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
    Si Shi, Shunrong Ji, Yi Qin, Jin Xu, Bo Zhang, Wenyan Xu, Jiang Liu, Jiang Long, Chen Liu, Liang Liu, Quanxing Ni, Xianjun Yu
    Cancer Letters.2015; 360(2): 227.     CrossRef
  • Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery
    Sung Hwan Kim, Jong Hoon Lee, Guk Jin Lee, Songmi Jeong, Yoo-Kang Kwak, Hoon-Kyo Kim, Deog Gon Cho, Young Ha Park, Mina Yu, Sei Chul Yoon
    Medicine.2015; 94(24): e955.     CrossRef
  • Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival
    Elba C. Etchebehere, John C. Araujo, Patricia S. Fox, Nancy M. Swanston, Homer A. Macapinlac, Eric M. Rohren
    Journal of Nuclear Medicine.2015; 56(8): 1177.     CrossRef
  • Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT
    Eric M. Rohren, Elba C. Etchebehere, John C. Araujo, Brian P. Hobbs, Nancy M. Swanston, Michael Everding, Tracy Moody, Homer A. Macapinlac
    Journal of Nuclear Medicine.2015; 56(10): 1507.     CrossRef
  • 11,685 View
  • 67 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Case Report
Sarcoidosis Mimicking Cancer Metastasis Following Chemotherapy for Ovarian Cancer
Mi Hyun Kim, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Min Ki Lee, Dong Soo Suh
Cancer Res Treat. 2013;45(4):354-358.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.354
AbstractAbstract PDFPubReaderePub
We report on a rare case of sarcoidosis that developed after chemotherapy for ovarian cancer, and mimicked a cancer metastasis. A 52-year-old female diagnosed with stage III ovarian cancer underwent curative surgery and postoperative chemotherapy. Four months later, her whole-body positron emission tomography and computed tomography (CT) scan showed high uptake in the mediastinal lymph nodes, and ovarian cancer recurrence was suspected. Biopsy of the mediastinal lymph nodes and subcutaneous nodules revealed noncaseating granulomas. These lesions resolved spontaneously without treatment; however, newly developed perilymphatic and centrilobular nodules were observed on follow-up chest CT. Surgical biopsy of these lesions also showed noncaseating granulomas. She was finally diagnosed with sarcoidosis.

Citations

Citations to this article as recorded by  
  • Sarcoidosis-Like Reaction After Chemotherapy Mimicking Metastasis in a Patient With Two Synchronous Tumors: A Case Report
    Sandra Silva, João Fernandes, Sérgio Campainha, Agostinho Sanches, Cristiana Marques
    Cureus.2024;[Epub]     CrossRef
  • A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a review of related literature
    Hui Lv, Yi Shao, Qiu-Song Chen, Wen-Jing Song, Li-Na Peng, Dian-Sheng Zhong
    Journal of Cancer Research and Clinical Oncology.2023; 149(16): 15287.     CrossRef
  • Subcutaneous sarcoidosis (Darier–Roussy sarcoidosis) with extensive disease on positron emission tomography: A case report and review of the literature
    Paul Youn, Roslyn J. Francis, Henry Preston, Fiona Lake
    Respirology Case Reports.2022;[Epub]     CrossRef
  • De Novo Presentation of Sarcoidosis on Restaging FDG PET/CT in Rectal Carcinoma With Self-resolution
    Sampath Santhosh, Godwin Jeeva, Raja Thirumalairaj
    Clinical Nuclear Medicine.2021; 46(1): e40.     CrossRef
  • Sarcoid-Like Reaction after Complete Remission of Malignancy: CT and 18F-FDG PET/CT Features for the Differential Diagnosis from Lymph Node Metastasis
    Hyun Ji Kang, Yookyung Kim, June Young Bae, Jung Hyun Chang, Soo-Hyun Lee
    Journal of the Korean Society of Radiology.2021; 82(4): 903.     CrossRef
  • Subcutaneous sarcoidosis of the upper and lower extremities: A case report and review of the literature
    Raman Mehrzad, Julia Festa, Reena Bhatt
    World Journal of Clinical Cases.2019; 7(17): 2505.     CrossRef
  • Endometriosis resembling endometrial cancer in a postmenopausal patient
    B. Suchońska, M. Gajewska, A. Zyguła, M. Wielgoś
    Climacteric.2018; 21(1): 88.     CrossRef
  • Multiorgan Involvement of Chemotherapy-Induced Sarcoidosis Mimicking Progression of Lymphoma on FDG PET/CT
    Prateek Sanan, Yang Lu
    Clinical Nuclear Medicine.2017; 42(9): 702.     CrossRef
  • Coexistence of sarcoidosis and metastatic lesions: A diagnostic and therapeutic dilemma (Review)
    Christoph Spiekermann, Meike Kuhlencord, Sebastian Huss, Claudia Rudack, Daniel Wei�
    Oncology Letters.2017;[Epub]     CrossRef
  • Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma – experience of single institution and a review of literature
    Lucka Boltezar, Ivana Zagar, Barbara Jezersek Novakovic
    Radiology and Oncology.2016; 50(4): 355.     CrossRef
  • Discovery of Splenic Sarcoidosis Concurrent with the Diagnosis of Ovarian Cancer: A Case Report
    Eun-Heui Kim, Seung-Geun Lee, Ki-Hyung Kim, Young-Mi Seol, Eun-Kyoung Park, Dong-Wan Koo, Na-Kyoung Hwang, In-Sub Han, Moon-Won Lee, Sung-Yong Han, Geun-Tae Kim, Hee-Sang Tag
    Journal of Rheumatic Diseases.2016; 23(2): 130.     CrossRef
  • Sarcoidosis in gastric cancer at the time of diagnosis: A case report
    YANG JIAO, JIE NING, WEN-DI ZHAO, YAN-LI LI, HONG-YANG WU, KANG-SHENG GU
    Oncology Letters.2015; 9(3): 1159.     CrossRef
  • Sarcoidosis of female reproductive organs in a postmenopausal woman
    Monika Zurkova, Marie Turkova, Tomas Tichy, Radovan Pilka, Vitezslav Kolek, Eva Kriegova
    Menopause.2015; 22(5): 549.     CrossRef
  • Sarcoidosis Occurring After Solid Cancer
    Aurélie Grados, Mikael Ebbo, Emmanuelle Bernit, Véronique Veit, Karin Mazodier, Rodolphe Jean, Diane Coso, Thérèse Aurran-Schleinitz, Florence Broussais, Reda Bouabdallah, Gwenaelle Gravis, Anthony Goncalves, Marc Giovaninni, Pascal Sève, Bruno Chetaille,
    Medicine.2015; 94(28): e928.     CrossRef
  • Sarcoid‐like reaction mimicking vaginal cancer recurrence
    Michinori Mayama, Masato Yoshihara, Mayu Ukai, Shinya Kondo, Yasuyuki Kishigami, Hidenori Oguchi
    Journal of Obstetrics and Gynaecology Research.2015; 41(11): 1855.     CrossRef
  • Carboplatin/paclitaxel

    Reactions Weekly.2014; 1497(1): 14.     CrossRef
  • 13,952 View
  • 71 Download
  • 14 Web of Science
  • 16 Crossref
Close layer
Original Article
Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma
Joon Suk Park, Joon Young Choi, Seung Hwan Moon, Yong Chan Ahn, Jeeyun Lee, Dohun Kim, Kwhanmien Kim, Young Mog Shim
Cancer Res Treat. 2013;45(1):22-30.   Published online March 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.1.22
AbstractAbstract PDFPubReaderePub
PURPOSE
Parameters of positron emission tomography-computed tomography (PET-CT) were compared with the results of histopathologic examination in order to determine which can provide an objective indication of response after neoadjuvant chemoradiation for treatment of thoracic esophageal squamous cell carcinoma (SCC).
MATERIALS AND METHODS
Between August 2003 and January 2010, data on 25 patients who underwent neoadjuvant chemoradiation and subsequent resection for treatment of esophageal SCC were retrospectively reviewed. Changes in maximum standardized uptake value (DeltaSUVmax), metabolic tumor volume (DeltaMTV), and total lesion glycolysis (DeltaTLG) were analyzed by comparison with the histopathologic findings.
RESULTS
Pathologic complete remission (CR) for the main tumor was achieved in 11 patients. Postradiation esophagitis was observed in 10 patients. DeltaSUVmax of the main tumor was significantly greater in the CR group than in the partial response (PR) group (p=0.039), while DeltaMTV and DeltaTLG of the main tumor were not (p=0.141 and p=0.349, respectively). The cut-off DeltaSUVmax value for CR was estimated as 72.1%, indicating significantly better accuracy than visual interpretation (p=0.045). Of the 48 involved lymph nodes, DeltaSUVmax and DeltaMTV of lymph nodes were significantly greater in the CR group than in the PR group (p=0.045 and p=0.014, respectively), while DeltaTLG was not (p=0.063). The cut-off value of DeltaSUVmax for prediction of CR in lymph nodes was calculated as 50.67%.
CONCLUSION
PET-CT could be used for prediction of response to neoadjuvant treatment in thoracic esophageal SCC. DeltaSUVmax may be a more significant predictor for CR after neoadjuvant chemoradiation than DeltaTLG and DeltaMTV.

Citations

Citations to this article as recorded by  
  • PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy
    Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Kohei Kemuriyama, Yoshihiro Sasaki, Kazuhiro Imai, Eri Maeda, Yoshihiro Minamiya
    Annals of Surgical Oncology.2022; 29(2): 1336.     CrossRef
  • Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment
    Wei-Hsiang Feng, Ying-Yi Chen, Yen‐Shou Kuo, Kuan-Hsun Lin, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang
    BMC Cancer.2022;[Epub]     CrossRef
  • SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
    Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Yoshihiro Sasaki, Kazuhiro Imai, Yoshihiro Minamiya
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • 18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy
    Seokmo Lee, Yunseon Choi, Geumju Park, Sunmi Jo, Sun Seong Lee, Jisun Park, Hye-Kyung Shim
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
    Ben M. Eyck, Barbera D. Onstenk, Bo J. Noordman, Daan Nieboer, Manon C. W. Spaander, Roelf Valkema, Sjoerd M. Lagarde, Bas P. L. Wijnhoven, J. Jan B. van Lanschot
    Annals of Surgery.2020; 271(2): 245.     CrossRef
  • Utility of positron emission–computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation
    Jiyun Lee, Joon Young Choi, Sung Won Lim, Myung-Ju Ahn, Keunchil Park, Jae Il Zo, Young Mog Shim, Dongryul Oh, Jong-Mu Sun
    European Journal of Cardio-Thoracic Surgery.2020; 58(5): 1019.     CrossRef
  • Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis
    Didi J.J.M. de Gouw, Bastiaan R. Klarenbeek, Mitchell Driessen, Stefan A.W. Bouwense, Frans van Workum, Jurgen J. Fütterer, Maroeska M. Rovers, Richard P.G. ten Broek, Camiel Rosman
    Journal of Thoracic Oncology.2019; 14(7): 1156.     CrossRef
  • Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
    Won Kyung Cho, Dongryul Oh, Yong Chan Ahn, Young Mog Shim, Jae Ill Zo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park
    Oncotarget.2017; 8(2): 3542.     CrossRef
  • Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management
    Mian Xi, Steven H. Lin
    EMJ Oncology.2017; : 78.     CrossRef
  • Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma
    Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Ichiko Yamakita, Tomoaki Kurokawa, Morihito Okada
    The Annals of Thoracic Surgery.2016; 102(4): 1132.     CrossRef
  • PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma
    Hui Yuan, Daniel K.H. Tong, Varut Vardhanabhuti, Simon Y.K. Law, Keith W.H. Chiu, Pek-Lan Khong
    Nuclear Medicine Communications.2016; 37(9): 947.     CrossRef
  • Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival
    K. E. O’Sullivan, E. T. Hurley, J. P. Hurley
    Gastroenterology Research and Practice.2015; 2015: 1.     CrossRef
  • Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
    Arpit Chhabra, Leonard T Ong, Deborah Kuk, Geoffrey Ku, David Ilson, Yelena Y Janjigian, Abraham Wu, Heiko Schöder, Karyn A Goodman
    British Journal of Cancer.2015; 113(12): 1658.     CrossRef
  • 12,780 View
  • 55 Download
  • 13 Crossref
Close layer
Case Report
Calcified Carcinoma of the Gallbladder with Calcified Nodal Metastasis Presenting as a Porcelain Gallbladder: A Case Report
Eun Joo Yun, Dae Young Yoon, Chul Soon Choi, Sang Hoon Bae, Young Lan Seo, Suk Ki Chang, Kyoung Ja Lim, Jung Hye Kwon, Mi Jung Kwon, Eun Sook Nam
Cancer Res Treat. 2011;43(1):71-74.   Published online March 31, 2011
DOI: https://doi.org/10.4143/crt.2011.43.1.71
AbstractAbstract PDFPubReaderePub
Porcelain gallbladder is regarded as a risk factor of gallbladder cancer. A porcelain gallbladder with calcified regional lymph nodes was found using computed tomography (CT) and magnetic resonance imaging (MRI) in a 43-year-old man who presented with nausea, vomiting, and abdominal pain. His cholecystectomy specimen showed diffuse wall thickening and contained small gallstones. Histological examination revealed diffuse infiltrative adenocarcinoma with extensive intratumoral calcification (calcified carcinoma). The majority of the calcified material was located within or replaced the tumor glands, and was not found in the stroma. A lymph node was totally replaced with a calcified metastatic adenocarcinoma. To the best of our knowledge, only one case of calcified lymph node metastasis from a calcified carcinoma of the gallbladder has been previously reported in the literature. We herein add a case of calcified carcinoma of the gallbladder with calcified lymph node metastasis, presenting as a porcelain gallbladder on CT and MRI.

Citations

Citations to this article as recorded by  
  • A porcelain gallbladder and a rapid tumor dissemination
    Juan-Ramón Gómez-López, Beatriz De Andrés-Asenjo, Christian Ortega-Loubon
    Annals of Medicine and Surgery.2014; 3(4): 119.     CrossRef
  • Porcelain Gallbladder: A Benign Process or Concern for Malignancy?
    Thomas Schnelldorfer
    Journal of Gastrointestinal Surgery.2013; 17(6): 1161.     CrossRef
  • 12,192 View
  • 74 Download
  • 2 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP